Résumé
Background-The European Randomized study of Screening for Prostate Cancer (ERSPC) has shown a 21% reduction in prostate cancer (PC) mortality and a 1•6-fold increase in PC incidence with PSA-based screening (at 13 years of follow-up). We evaluated PC incidence by risk category at diagnosis across the arms in order to assess the potential impact on PC mortality.Design, setting, and participants-Information on arm, centre, T and M stage, Gleason score, serum PSA at diagnosis, age at randomization, follow-up time and vital status were extracted from the ERSPC database. Four risk categories at diagnosis were defined: 1-low, 2intermediate, 3-high, 4-metastatic disease. PSA (<=100 / >100) was used as the indicator of metastasis. Outcome measurements and statistical analysis-Incidence rate ratios (RR) for screening versus control arm by risk category at diagnosis and follow-up time were calculated using Poisson regression analysis for 7 centres. Follow-up was truncated at 13 years. Missing data were imputed using chained equations. The analyses were carried out on an intention-to-treat basis.Results and limitations: In the screening arm, 7408 PCa cases were diagnosed and 6107 in the control arm. The proportion of missing stage, Gleason score, or PSA value was comparable in the two arms (8% vs 10%), but differed among centres. The IRRs were elevated in the screening arm for the low-risk (IRR: 2.14; 95% CI, 2.03–2.25) and intermediate-risk (IRR: 1.24; 95% CI, 1.16–1.34) categories at diagnosis, equal to unity for the high-risk category at diagnosis (IRR: 1.00; 95% CI, 0.89–1.13), and reduced for metastatic disease at diagnosis (IRR: 0.60; 95% CI, 0.52–0.70). The IRR of metastatic disease had temporal pattern similar to mortality, shifted forwards an average of almost 3 yr, although the mortality reduction was smaller.Conclusions: The results confirm a reduction in metastatic disease at diagnosis in the screening arm, preceding mortality reduction by almost 3 yr.Patient summary: The findings of this study indicate that the decrease in metastatic disease at diagnosis is the major determinant of the prostate cancer mortality reduction in the European Randomized study of Screening for Prostate Cancer.